
Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Culturally Competent Menopause Care: Lisa Taylor-Swanson, PhD
3
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
4
Stereotactic Body Radiation Therapy Equally Effective as Surgery in Stage I NSCLC
5















































